Japanese encephalitis
From Wikipedia, the free encyclopedia
 |
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (March 2007) |
| Japanese Encephalitis | |
| Classification and external resources | |
| ICD-10 | A83.0 |
|---|---|
| ICD-9 | 062.0 |
| DiseasesDB | 7036 |
| eMedicine | med/3158 |
| MeSH | D004672 |
| Japanese encephalitis | ||||||||
|---|---|---|---|---|---|---|---|---|
| Virus classification | ||||||||
|
Japanese encephalitis (Japanese: 日本脳炎, Nihon-nōen; previously known as Japanese B encephalitis to distinguish it from von Economo's A encephalitis) is a disease caused by the mosquito-borne Japanese encephalitis virus. The Japanese encephalitis virus is a virus from the family Flaviviridae. Domestic pigs and wild birds are reservoirs of the virus; transmission to humans may cause severe symptoms. One of the most important vectors of this disease is the mosquito Culex tritaeniorhynchus. This disease is most prevalent in Southeast Asia and the Far East.
Contents |
[edit] Epidemiology
Japanese encephalitis (JE) is the leading cause of viral encephalitis in Asia, with 30,000–50,000 cases reported annually. Case-fatality rates range from 0.3% to 60% and depends on the population and on age. Rare outbreaks in U.S. territories in Western Pacific have occurred. Residents of rural areas in endemic locations are at highest risk; Japanese encephalitis does not usually occur in urban areas. Countries which have had major epidemics in the past, but which have controlled the disease primarily by vaccination, include China, Korea, Japan, Taiwan and Thailand. Other countries that still have periodic epidemics include Vietnam, Cambodia, Myanmar, India, Nepal, and Malaysia. Japanese encephalitis has been reported on the Torres Strait Islands and two fatal cases were reported in mainland northern Australia in 1998. The spread of the virus in Australia is of particular concern to Australian health officials due to the unplanned introduction of Culex gelidus, a potential vector of the virus, from Asia. However, the current presence on mainland Australia is minimal. Human, cattle and horses are dead-end hosts and disease manifests as fatal encephalitis. Swine acts as amplifying host and has very important role in epidemiology of the disease. Infection in swine is asymptomatic, except in pregnant sows, when abortion and fetal abnormalities are common sequelae. Infection in Humans occur in the ear, particularly the cochlea. The most important vector is C. tritaeniorhynchus, which feeds on cattle in preference to humans, it has been proposed that moving swine away from human habitation can divert the mosquito away from humans and swine. The natural host of the Japanese encephalitis virus is bird, not human, and many believe the virus will therefore never be completely eliminated.
[edit] Clinical features
Japanese encephalitis has an incubation period of 5 to 15 days and the vast majority of infections are asymptomatic: only 1 in 250 infections develop into encephalitis.
Severe rigors mark the onset of this disease in humans. Fever, headache and malaise are other non-specific symptoms of this disease which may last for a period of between 1 and 6 days. Signs which develop during the acute encephalitic stage include neck rigidity, cachexia, hemiparesis, convulsions and a raised body temperature between 38 and 41 degrees Celsius. Mental retardation developed from this disease usually leads to coma. Mortality of this disease varies but is generally much higher in children. Transplacental spread has been noted. Life-long neurological defects such as deafness, emotional lability and hemiparesis may occur in those who have had central nervous system involvement. In known cases some effects also include, nausea, headache, fever, vomiting and sometimes swelling of the testicles.
A recent investigation has found that neural progenitor cells (NPC) are permissive to Japanese encephalitis virus (JEV) infection both in vivo and in vitro, which leads to their growth retardation. The pathophysiological relevance of these observations was supported by profound decrement in actively proliferating NPCs in the subventricular zone (SVZ) of JEV-infected animals. Infection of the NPCs and suppression of their proliferation might be primarily responsible for dysregulated neurogenesis in survivors of JE and development of cognitive deficits in them. [1]
Increased microglial activation following JEV infection has been found to influence the outcome of viral pathogenesis. Microglias are the resident immune cells of the central nervous system (CNS) and have a critical role in host defense against invading microorganisms. Activated microglia secrete cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α), which can cause toxic effects in the brain. Additionally, other soluble factors such as neurotoxins, excitatory neurotransmitters, prostaglandin, reactive oxygen, and nitrogen species are secreted by activated microglia.
In a murine model of JE, it was found that in the hippocampus and the striatum, the number of activated microglia was more than anywhere else in the brain closely followed by that in the thalamus. In the cortex, number of activated microglia was significantly less when compared with other regions of the mouse brain. An overall induction of differential expression of proinflammatory cytokines and chemokines from different brain regions during a progressive JEV infection was also observed.
Although the net effect of the proinflammatory mediators is to kill infectious organisms and infected cells as well as to stimulate the production of molecules that amplify the mounting response to damage, it is also evident that in a nonregenerating organ such as brain, a dysregulated innate immune response would be deleterious. In JE the tight regulation of microglial activation appears to be disturbed, resulting in an autotoxic loop of microglial activation that possibly leads to bystander neuronal damage.[2]
[edit] Virology
The causative agent Japanese encephalitis virus is an enveloped virus of the genus flavivirus; it is closely related to the West Nile virus and St. Louis encephalitis virus. Positive sense single stranded RNA genome is packaged in the capsid, formed by the capsid protein. The outer envelope is formed by envelope (E) protein and is the protective antigen. It aids in entry of the virus to the inside of the cell. The genome also encodes several nonstructural proteins also (NS1,NS2a,NS2b,NS3,N4a,NS4b,NS5). NS1 is produced as secretory form also. NS3 is a putative helicase, and NS5 is the viral polymerase. It has been noted that the Japanese encephalitis virus (JEV) infects the lumen of the endoplasmic reticulum (ER)[3][4] and rapidly accumulates substantial amounts of viral proteins for the JEV.
Japanese Encephalitis is diagnosed by detection of antibodies in serum and CSF (cerebrospinal fluid) by IgM capture ELISA.[5]
[edit] Prevention
 |
It has been suggested that Japanese encephalitis vaccine be merged into this article or section. (Discuss) |
Infection with JEV confers life-long immunity. All current vaccines are based on the genotype III virus. A formalin-inactivated mouse-brain derived vaccine was first produced in Japan in the 1930s and was validated for use in Taiwan in the 1960s and in Thailand in the 1980s. The widespread use of vaccine and urbanisation has led to control of the disease in Japan, Korea, Taiwan and Singapore. The high cost of the vaccine, which is grown in live mice, means that poorer countries have not been able to afford to give it as part of a routine immunisation programme.
In the UK, the two vaccines used (but which are unlicensed) are JE-Vax and Green Cross, JE-Vax has subsequentaly been removed from market. Three doses are given at 0, 7–14 and 28–30 days. The dose is 1ml for children and adult, and 0.5ml for infants under 36 months of age. A new vaccine has been produced by Intercell biomedical ltd named IXIARO®, and requires only 2 doses, and is currently licensed in Australia, America and the EU.
The most common adverse effects are redness and pain at the injection site. Uncommonly, an urticarial reaction can develop about four days after injection. Because the vaccine is produced from mouse brain,[6] there is a risk of autoimmune neurological complications of around 1 per million vaccinations. However in the case of IXIARO® were the vaccine is not produced in mouse brains but in vitro using cell culture there is little adverse effects compared to the Placebo, the main side effects are Headache and myalgia.[7]
Neutralising antibody persists in the circulation for at least two to three years, and perhaps longer.[8][9] The total duration of protection is unknown, but because there is no firm evidence for protection beyond three years, boosters are recommended every two years for people who remain at risk.
There are a number of new vaccines under development. The mouse-brain derived vaccine is likely to be replaced by a cell-culture derived vaccine that is both safer and cheaper to produce. China licensed a live attenuated vaccine in 1988 and more than 200 million doses have been given; this vaccine is available in Nepal, Sri Lanka, South Korea and India. There is also a new chimeric vaccine based on the yellow fever 17D vaccine that is currently under development.[10]
[edit] Treatment
There is no specific treatment for Japanese encephalitis and treatment is supportive. There is no transmission from person to person and therefore patients do not need to be isolated.
The use of rosmarinic acid [11] and arctigenin has been shown to be effective in a mouse model of Japanese encephalitis,[12] but there is as yet no clinical evidence to support their use.
Recently it has been found that treatment with minocycline provides a complete protection against experimental JE. Minocycline, a semisynthetic tetracycline, is a safe drug commonly used for prolonged treatment of infections, rheumatoid arthritis, and acne vulgaris. Minocycline’s neuroprotective action is associated with marked decreases in (i) neuronal apoptosis, (ii) the level of active caspase, (iii) microgliosis, (iv) viral titer, and (v) the level of proinflammatory mediators. Furthermore, treatment with minocycline also improves the behavioral outcome following JE. Minocycline, which is in clinical trials for both Parkinson’s disease and Huntington’s disease, may be an ideal candidate for considering in a human trial for JE. It is an attractive candidate for clinical assessment because it is profoundly effective even when given after the inoculation of virus, lacks obvious significant toxic side effects, can be delivered systemically with relatively good CNS penetration and is reasonably inexpensive.[13]
[edit] References
- ^ Das S, Basu A. (August 2008). Japanese encephalitis virus infects neural progenitor cells and decreases their proliferation J. Neurochem. 106(4): 1624-36. doi: 10.1111/j.1471-4159.2008.05511.x; PMID: 18540995.
- ^ Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, Sen E, Basu A. (April 2007). Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia. 55(5):483-96. DOI 10.1002/glia.20474. PMID: 17203475.
- ^ He B (March 2006). "Viruses, endoplasmic reticulum stress, and interferon responses". Cell Death Differ. 13 (3): 393–403. doi:. PMID 16397582. http://www.nature.com/cdd/journal/v13/n3/full/4401833a.html.
- ^ Su HL, Liao CL, Lin YL (May 2002). "Japanese encephalitis virus infection initiates endoplasmic reticulum stress and an unfolded protein response". J. Virol. 76 (9): 4162–71. PMID 11932381. PMC: 155064. http://jvi.asm.org/cgi/content/full/76/9/4162.
- ^ Shrivastva A, Tripathi NK, Parida M, Dash PK, Jana AM, Lakshmana Rao PV (2008). "Comparison of a dipstick enzyme-linked immunosorbent assay with commercial assays for detection of Japanese encephalitis virus-specific IgM antibodies". J Postgrad Med 54 (3): 181–5. PMID 18626163. http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2008;volume=54;issue=3;spage=181;epage=185;aulast=Shrivastva.
- ^ Jelinek T (July 2008). "Japanese encephalitis vaccine in travelers". Expert Rev Vaccines 7 (5): 689–93. doi:. PMID 18564023. http://www.future-drugs.com/doi/abs/10.1586/14760584.7.5.689?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov.
- ^ EMEA Aproval of Vaccine http://www.emea.europa.eu/pdfs/human/opinion/Ixiaro_66231608en.pdf
- ^ Gambel JM, DeFraites R, Hoke C, et al. (1995). "Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series (letter)". J Infect Dis 171: 1074. PMID 7706798.
- ^ Kurane I, Takashi T (2000). "Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains". Vaccine 18 Suppl: 33–5. doi:. PMID 10821971. http://linkinghub.elsevier.com/retrieve/pii/S0264410X00000414.
- ^ Solomon T (2006). "Control of Japanese Encephalitis—within our grasp?". New England Journal of Medicine 355 (9): 869–871. doi:. PMID 16943399. http://content.nejm.org/cgi/content/full/355/9/869.
- ^ Swarup V, Ghosh J, Ghosh S, Saxena A, Basu A. (2007 Sept). Antiviral and anti-inflammatory effects of rosmarinic acid in an experimental murine model of Japanese encephalitis. Antimicrob Agents Chemother. 51(9):3367-70. doi:10.1128/AAC.00041-07. PMID: 17576830.
- ^ Swarup V, Ghosh J, Mishra MK, Basu A (March 2008). "Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan". J. Antimicrob. Chemother. 61 (3): 679–88. doi:. PMID 18230688. http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=18230688.
- ^ Mishra MK, Basu A. (Jun 2008). Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. J Neurochem. 105(5): 1582-95. doi: 10.1111/j.1471-4159.2008.05238.x. PMID: 18208541.
[edit] External links
- Clark, Michael; Kumar, Parveen J. (2002). Clinical Medicine (5th ed. ed.). London: W B Saunders. ISBN 0-7020-2579-8.
- Centers for Disease Control and Prevention Questions and Answers About Japanese Encephalitis
- Australian government Department of Health and Aging, Japanese Encephalitis, 2004
- Monath, TP (1986). "Pathobiology of the flaviviruses". in Schlesinger, Milton J.; Schlesinger, Sondra. The Togaviridae and Flaviviridae. New York: Plenum Press. pp. 375–440. ISBN 0-306-42176-3.
- UK Department of Health. (2006) Immunisation against Infectious Disease Chapter 20: Japanese Encephalitis
- WHO. [1]
- PATH's Japanese encephalitis project [2]
- Japanese encephalitis resource library [3]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
